Posters

"Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma”, Wilkinson Et al, AACR, 2019

Learn More

"Oncolytics Virus Replication Using Pelareorep and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses", Hofmeister et al, ASH, 2018

Learn More

"Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA", Pandha et al, SITC, 2018

Learn More

"Dose finding and safety study of Reovirus (Reo) with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final Results", Goel et al, ESMO, 2018

Learn More

"Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy", Grey Wilkinson et al, ASCO, 2018

Learn More

"Potentiating effect of reovirus in anti-PD1 therapy in colorectal cancer", Sanjay Goel et al, AACR, 2018

Learn More

"Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy", Grey Wilkinson et al, AACR, 2018

Learn More

"B and T lymphocyte attenuator (BTLA) and PD-L1 significantly upregulated in reovirus treated TRAMP-C2 tumours", Pandha et al, IOVC, 2018

Learn More

"A study of pelareorep in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP)”, Mahalingam et al, ASCO GI, 2018

Learn More

"Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients", Gutierrez et al, ESMO, 2017

Learn More

"Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)", Goel et al, ESMO, 2017

Learn More

"A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)", Bernstein et al, AACR, 2017

Learn More

"Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma", Mahalingam et al, EMSO, 2015

Learn More

"PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy", Mostafa et al, AACR, 2014

Learn More

"Combination therapy with reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses", Rajani et al, 2014

Learn More

"Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection", Parrish et al, ASH, 2014

Learn More

Publications

MOA – Immunity

“Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?” Davola & Mossman, OncoImmunology, 2019

Learn More

“Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds” Sivanandam et al, Molecular Therapy Oncolytics, 2019

Learn More

"Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)” Fountzilas et al, ASCO Abstract, 2019

Learn More

"Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model” Thirukkumaram et al, Blood Advances, 2019

Learn More

“Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer” Mostafa et al, Cancers, 2018

Learn More

"Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy" Ilett et al, Cancer Immunology Research, 2018

Learn More

"A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma" Mahalingam et al, Cancers, 2018

Learn More

"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer" Samson, BMJ Hepatology, 2016

Learn More

"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (REOLYSIN®) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma" Noonan, Molecular Therapy vol. 24 no. 6 jun. 2016 1151

Learn More

"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses" Rajani et al, Molecular Therapy, 2016. 24(1): p. 166-74

Learn More

"Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo" El-Sherbiny et al, The Journal of Translational Immunology, 2015. 180(1): p. 98-107

Learn More

"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells" Adair et al, International Journal of Cancer, 2013. 132(10): p. 2327-38

Learn More

"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients" Adair et al, Science Translational Medicine, 2012. 4(138): p. 138ra77

Learn More

"Oncolytic virus-initiated protective immunity against prostate cancer." Gujar et al, Molecular Therapy, 2011. 19(4): p. 797-804

Learn More

"Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumor immune priming" Steele et al, Molecular Cancer, 2011. 10: p. 20

Learn More

"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity" Gujar et al, Molecular Cancer Therapeutics, 2010. 9(11): p. 2924-33

Learn More

"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication" Prestwich et al, Clinical Cancer Research, 2009. 15(13): p. 4374-81

Learn More

"Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity" Errington et al, The Journal of Immunology, 2008. 180(9): p. 6018-6026

Learn More

"Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial" White et al, Gene Therapy, 2008. 15(12): p. 911-20

Learn More
MOA – Lysis

"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors" Villalona-Calero et al., Cancer, 2016. 122(6): p. 875-83

Learn More

"The combination of intravenous REOLYSIN® and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer" Mahalingam et al, BMC Cancer (2015) 15:513

Learn More

"REOLYSIN® is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer" Carew et al, Cell Death & Disease, 2013. 4: p. e728

Learn More

"Intravenous administration of REOLYSIN®, a live replication competent RNA virus is safe in patients with advanced solid tumors" Gollamudi et al, Invest New Drugs, 2010. 28(5): p. 641-9

Learn More

"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells" Sei et al, Molecular Cancer, 2009. 8: p. 47

Learn More

"Oncolytic viral therapy for human pancreatic cancer cells by reovirus" Etoh et al, Clinical Cancer Research, 2003. 9(3): p. 1218-23

Learn More

"Reovirus oncolysis of human breast cancer" Norman et al, Human Gene Therapy, 2002. 13(5): p. 641-52

Learn More